Flagship Pioneering Unveils Inzen Therapeutics
Company developing new class of transformative medicines based on Thanokine Biology
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Jan. 13, 2021 /PRNewswire/ Flagship Pioneering, a life science platforms company, today announced the unveiling of Inzen Therapeutics. Flagship created Inzen in 2017 to discover and develop a novel class of medicines based on a previously unrecognized area of biology that exerts broad and fundamental influence on cell state, discovered and named Thanokine
™ Biology by Flagship s scientists. Flagship also announced the appointment of industry veteran Volker Herrmann, M.D., M.B.A. as the company s new Chief Executive Officer and Partner at Flagship Pioneering, succeeding founding CEO Douglas Cole. Dr. Cole is Chairman of Inzen and Managing Partner at Flagship.
News Category Global Banking & Finance Reviews
Tessera Therapeutics Attracts Over $230M in Series B Financing to Advance ‘Gene Writing’ – A New Category in Genetic Medicine
Tessera Therapeutics Attracts Over $230M in Series B Financing to Advance ‘Gene Writing’ – A New Category in Genetic Medicine Tessera Therapeutics, an early-stage life sciences company founded by Flagship Pioneering, announced today that it has raised over $230M in Series B financing. The round was co-led by Alaska Permanent Fund Corporation, Altitude Life Science Ventures, and SoftBank Vision Fund 2
i, with participation from Qatar Investment Authority (QIA) and others. Tessera, unveiled in July 2020 after multiple years of in-house innovation within Flagship Labs, is pioneering Gene Writinga new technology that has the ability to write therapeutic instructions into the genome to treat diseases at their source. By changing any base pair to another, making small insertions or deletions, and wri
Share this article
Share this article
LINKÖPING, Sweden, Jan. 12, 2021 /PRNewswire/ A perspective review article titled Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis was recently published in
Frontiers in Endocrinology as part of a special issue of Non-Alcoholic Steatohepatitis (NASH) Metabolic Contributors and Therapeutic Targets. Authored by scientific experts from Axcella Health, AMRA Medical, Linköping University, and Virginia Commonwealth University (VCU), this paper describes the link between muscle composition and chronic liver diseases, including non-alcoholic fatty liver disease (NAFLD). It discusses in depth the scientific basis of underlying factors outside of the liver to treat NAFLD – affecting nearly one-quarter of the world s adult population.
How Investment in Open Innovation Can Lead Us to More Accessible Health Care worth.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from worth.com Daily Mail and Mail on Sunday newspapers.